Spanish pharma companies plan to continue extending their footprint around the world

3 June 2014

Spanish pharmaceutical companies have developed a strong strategy in the last years to expand their products around the world, but these processes do not finish in selling drugs abroad, reports The Pharma Letter’s correspondent in Spain.

Also, almost every one of them has opened up new affiliates, commercial offices and production or R&D sites in other countries. In this sense, the favorite places were European countries, the USA or others regions, such as Latin America or Asia, for instance.

With regard to global presence, it is right to highlight Grifols (GRLS: MC), with 24 affiliates in Europe, North America, South America, Asia Pacific and Southeast Asia. Also, the Barcelona-based company has industrial facilities in the USA (Clayton, North Carolina; Melville, New York; and Los Angeles, California), Mexico (Guadalajara), Switzerland (Dudinguen), and Australia (Melbourne). People from the company declined to make statements about their plans for the future.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical